| Positron Introduces Attrius and Tech-Assist at Society of Nuclear Medicine Annual Meeting |
| News - Financial News |
|
--(www.FinancialNewsUSA.com)-- 07/02/2009 - Positron Corporation (OTCBB: POSC) (the "Company"), a molecular imaging company focused on Nuclear Cardiology, introduced their new cardiac optimized PET scanner, the Attrius(TM) and portable FDG dose administration system, the Tech-Assist(TM), during their participation at the Society of Nuclear Medicine Annual Meeting held this June in Toronto, Canada (www.snm.org). The conference was a tremendous event to showcase Positron's much anticipated launch of the Attrius(TM) and Tech-Assist(TM). Positron's products were met with industry-wide acclaim and interest from both the cardiology and oncology fields. The Attrius(TM) PET scanner, recently 510(k) approved by the FDA, was designed for cardiac optimized PET imaging yet offers standard whole body imaging capabilities. Whole body imaging with sodium fluoride is becoming a viable and relevant alternative to SPECT imaging due to the recent molybdenum shortage. Positron's Tech-Assist(TM) is a portable dose administration system that reduces worker exposure during PET injection applications, including FDG, sodium fluoride for whole body bone imaging, as well as, new F-18 agents that are injected by a syringe. "The Society of Nuclear Medicine meeting exceeded all our expectations. The radiation exposure protection provided by the Tech-Assist(TM) has become a necessity and now a true priority for all. We received tremendous interest for the Attrius(TM) as Cardiac PET has become the standard in nuclear cardiology. The Attrius(TM) also saw interest for whole body bone imaging with sodium fluoride," stated John Zehner, COO of Positron Corporation. "The reoccurring Molybdenum shortage is causing the industry to demand alternatives, such as PET. It was apparent based on customer interaction that our product and service strategy is aligned perfectly with ongoing industry needs. Positron products are positioned as important enablers in the growth of the industry." About Positron Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron has four primary products: the Attrius(TM), a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the Tech-Assist(TM), a radiopharmaceutical injection shield. Over 150 Positron products are installed in hospitals and medical offices around the world. More information about Positron is available at www.positron.com. Forward Looking Statements: This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. For further information please contact Positron Corporation at (866)-613-7587. 
|